Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

First Quarter 2016 Financial Results

Jean-Paul Clozel CEO "With the business performing
better than anticipated, even while launching new
products and investing in future products, I am
confident to upgrade our financial guidance."

Jean-Paul Clozel CEO "With the business performing
better than anticipated, even while launching new
products and investing in future products, I am
confident to upgrade our financial guidance."

Global Actelion

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 17:30:06 CET 29/04/2016
CHF 155,00Up Down image
-0,80 (-0,51%)
 

ANNUAL REPORT

Image for ANNUAL REPORT

On 09 February 2016 Actelion published the financial results for 2015 accompanied by the publication of the company's Annual Report.

Image for ANNUAL REPORT

On 09 February 2016 Actelion published the financial results for 2015 accompanied by the publication of the company's Annual Report.

AGM 2016

Image for AGM 2016

The Annual General Meeting 2016 to approve the Business Report of 2015 will be held on:

WEDNESDAY, 4 MAY 2016, 10:00 A.M.

The Annual General Meeting 2016 to approve the Business Report of 2015 will be held on:

WEDNESDAY, 4 MAY 2016, 10:00 A.M.

Sustainability Report

Image for Sustainability Report

In preparing our first Sustainability Report, we chose to follow the G4 Sustainability Reporting Guidelines issued by the Global Reporting Initiative (GRI).

 

Image for Sustainability Report

In preparing our first Sustainability Report, we chose to follow the G4 Sustainability Reporting Guidelines issued by the Global Reporting Initiative (GRI).